Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

26.01 -0.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.63

Max

26.16

Põhinäitajad

By Trading Economics

Sissetulek

191K

-51M

Müük

6.7M

106M

Aktsiakasum

-0.46

Kasumimarginaal

-47.808

Töötajad

1,784

EBITDA

-2.1M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+39.62% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

826M

2.9B

Eelmine avamishind

26.13

Eelmine sulgemishind

26.01

Uudiste sentiment

By Acuity

50%

50%

171 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. aug 2026, 23:51 UTC

News

Enova International's subsidiary issued $300.89 million in notes, contributing to positive sentiment. The stock is higher in after-market trading, despite recent volatility.

21. aug 2026, 23:46 UTC

News

Home Depot expands roles for three executives, awarding $500,000 in stock grants. Shares were roughly flat during after-market hours following the announcement.

21. aug 2026, 23:41 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, bolstered by gains from UnitedHealth Group and Merck, despite broader market declines.

21. aug 2026, 23:36 UTC

News

Coty Inc reported a fourth-quarter revenue beat but issued weak guidance, resulting in shares trading lower in after-market hours.

21. aug 2026, 23:31 UTC

Correlated Moves
News

Ethereum's price reached $2,371 today, driven by anticipation of Pepeto's Binance listing and Bitcoin's rally past $79,000, boosting market sentiment.

21. aug 2026, 23:26 UTC

Correlated Moves
News

Citigroup Inc shares are lower during after-market hours, reflecting a slight decline amid broader market trends influenced by geopolitical tensions and bargain hunting.

21. aug 2026, 23:21 UTC

Correlated Moves
News
Social Media

Coinbase Global Inc is rising in after-market trading, supported by Bitcoin's significant gain. The company also launched a feature for immediate token access.

21. aug 2026, 23:06 UTC

News

Verizon Communications is deploying resources in response to a potential tropical storm in Hawaii, contributing to lower shares after Friday's close.

21. aug 2026, 23:06 UTC

Correlated Moves
News

KKR & Co Inc reported a net asset value of $8.49 billion as of July 31, contributing to positive sentiment in after-market trading.

21. aug 2026, 23:01 UTC

Social Media
News

Applied Optoelectronics Inc. plans to sell up to $600 million in shares, contributing to a decline in after-market trading amid dilution concerns.

21. aug 2026, 23:01 UTC

News

Hess Midstream LP shares are advancing in after-market trading following a dividend increase and improved free cash flow, despite lower EBITDA and net income.

21. aug 2026, 23:01 UTC

News

Texas Pacific Land Corp shares are higher in after-hours trading, with a market capitalization of $26.49 billion reflecting strong long-term performance.

21. aug 2026, 23:01 UTC

News
Social Media

Sigma Lithium Corp resumes full operations under a new agreement in Brazil, targeting 240,000 tonnes of lithium oxide concentrate. Shares are advancing in after-market trading.

21. aug 2026, 23:01 UTC

News

Spectrum Brands Holdings Inc shares are higher in after-market trading. The company expects low-single-digit revenue growth for fiscal year 2026 amid ongoing cost pressures.

21. aug 2026, 22:01 UTC

News

Cytek Biosciences shares are lower in after-market hours following a jury's $56 million damages award to Beckman Coulter for patent infringement.

21. aug 2026, 20:07 UTC

News
Social Media

Microsoft shares are higher, supported by bullish options activity and a reaffirmed AAA rating from Moody's. The company is part of a $615 billion AI investment group.

21. aug 2026, 20:07 UTC

Social Media
News

Palantir Technologies shares are higher today amid increased options trading and positive sentiment, with Deutsche Bank reiterating a $200 price target.

21. aug 2026, 20:07 UTC

News

Aflac shares are lower today as Japan Post sold 12,700 shares, contributing to negative sentiment amid broader market declines since Thursday's close.

21. aug 2026, 20:07 UTC

News

United Parcel Service shares are trading lower as Zacks cuts Q3 EPS estimate to $1.60. Susquehanna raises target price to $120, maintaining a neutral rating.

21. aug 2026, 20:07 UTC

News

Barclays maintains an Overweight rating on Hims & Hers Health, lowering its price target to $35. Shares are trading higher amid positive market sentiment.

21. aug 2026, 20:07 UTC

News
Correlated Moves

The USD/SEK is trading lower today, continuing a decline since Thursday's close. Earlier in the session, the dollar rebounded from a session low.

21. aug 2026, 20:06 UTC

News

Nu Holdings is higher today, buoyed by a rise in Bitcoin prices following the U.S. Treasury's announcement to double long-dated bond buybacks.

21. aug 2026, 20:06 UTC

News
Correlated Moves

Gold prices are rising, reaching a near three-month high, driven by U.S. Treasury bond buybacks and President Trump's shift in Iran policy.

21. aug 2026, 20:06 UTC

Correlated Moves
News

First Western Financial promotes Brian Weldon to Regional President and Bryce Parietti and Rob Miles to Market Presidents, with shares trading higher today.

21. aug 2026, 20:06 UTC

News

Liquidity Services shares are higher after announcing CEO Bill Angrick's presentation at the Midwest IDEAS Investor Conference on August 26, 2026, in Chicago.

21. aug 2026, 20:06 UTC

News

Palo Alto Networks shares are higher following multiple analyst price target increases, including Cantor Fitzgerald's raise to $425 from $340.

21. aug 2026, 20:06 UTC

News

Citizens Inc shares are lower today, continuing a decline since Thursday amid broader market downturns. The stock remains below its 20-day moving average.

21. aug 2026, 20:06 UTC

News
Social Media

Stoke Therapeutics shares rise following analyst reinstatement with Overweight rating and $40 price target, amid positive sentiment for zorevunersen’s phase III EMPEROR trial.

21. aug 2026, 20:06 UTC

News

T Rowe Price shares are lower as the company pursues its acquisition of F/M Investments, which manages over $10 billion in ETF assets.

21. aug 2026, 20:06 UTC

News

Salesforce Inc is higher as investor interest grows ahead of its August 26 earnings report, with a revenue target of $11.3 billion for Q2.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

39.62% tõus

12 kuu keskmine prognoos

Keskmine 36.33 USD  39.62%

Kõrge 45 USD

Madal 27 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

171 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat